Cargando…
Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants
BACKGROUND: Little is known about physiological anticoagulation effects via antithrombin III (AT III) and protein C/S (PC/PS) in patients using new oral anticoagulants (NOACs). METHODS: We evaluated 120 consecutive patients with non-valvular atrial fibrillation (AF) receiving NOACs. Patients were ra...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388056/ https://www.ncbi.nlm.nih.gov/pubmed/28416977 http://dx.doi.org/10.1016/j.joa.2016.07.011 |
_version_ | 1782521061685854208 |
---|---|
author | Nagao, Tomoyuki Hunakubo, Hiroshi Suzuki, Mayu Kataoka, Takashi Okumura, Satoshi Shinoda, Norihiro Harada, Ken Kato, Bunichi Kato, Masataka Marui, Nobuyuki Sakai, Shinichi Amano, Tetsuya Murohara, Toyoaki |
author_facet | Nagao, Tomoyuki Hunakubo, Hiroshi Suzuki, Mayu Kataoka, Takashi Okumura, Satoshi Shinoda, Norihiro Harada, Ken Kato, Bunichi Kato, Masataka Marui, Nobuyuki Sakai, Shinichi Amano, Tetsuya Murohara, Toyoaki |
author_sort | Nagao, Tomoyuki |
collection | PubMed |
description | BACKGROUND: Little is known about physiological anticoagulation effects via antithrombin III (AT III) and protein C/S (PC/PS) in patients using new oral anticoagulants (NOACs). METHODS: We evaluated 120 consecutive patients with non-valvular atrial fibrillation (AF) receiving NOACs. Patients were randomly divided into three groups: a dabigatran group (DG, N=40), a rivaroxaban group (RG, N=40) or an apixaban group (AG, N=40). A warfarin group (WG, N=40) was matched with NOAC groups for age, sex and type of AF during the same time period. Blood samples were obtained in pretreatment, trough and peak phases to measure the activity of physiological coagulation inhibitors, including AT III and PC/PS or thrombus formation markers such as D-dimer and thrombin–antithrombin complex (TAT). RESULTS: D-dimer, TAT and AT III values for the NOAC groups were equivalent in the peak and trough phases. PC/PS activity in both phases was equally maintained in the pretreatment phase in the NOAC groups, while the activity in the WG was significantly suppressed in steady state. Moreover, no differences in trends for PC/PS activity were observed among NOAC groups. CONCLUSIONS: PC/PS activity was constant in both peak and trough phases in the patients on NOACs compared with activity of those on warfarin. In addition, there was no difference in the findings among NOACs. |
format | Online Article Text |
id | pubmed-5388056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-53880562017-04-17 Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants Nagao, Tomoyuki Hunakubo, Hiroshi Suzuki, Mayu Kataoka, Takashi Okumura, Satoshi Shinoda, Norihiro Harada, Ken Kato, Bunichi Kato, Masataka Marui, Nobuyuki Sakai, Shinichi Amano, Tetsuya Murohara, Toyoaki J Arrhythm Original Article BACKGROUND: Little is known about physiological anticoagulation effects via antithrombin III (AT III) and protein C/S (PC/PS) in patients using new oral anticoagulants (NOACs). METHODS: We evaluated 120 consecutive patients with non-valvular atrial fibrillation (AF) receiving NOACs. Patients were randomly divided into three groups: a dabigatran group (DG, N=40), a rivaroxaban group (RG, N=40) or an apixaban group (AG, N=40). A warfarin group (WG, N=40) was matched with NOAC groups for age, sex and type of AF during the same time period. Blood samples were obtained in pretreatment, trough and peak phases to measure the activity of physiological coagulation inhibitors, including AT III and PC/PS or thrombus formation markers such as D-dimer and thrombin–antithrombin complex (TAT). RESULTS: D-dimer, TAT and AT III values for the NOAC groups were equivalent in the peak and trough phases. PC/PS activity in both phases was equally maintained in the pretreatment phase in the NOAC groups, while the activity in the WG was significantly suppressed in steady state. Moreover, no differences in trends for PC/PS activity were observed among NOAC groups. CONCLUSIONS: PC/PS activity was constant in both peak and trough phases in the patients on NOACs compared with activity of those on warfarin. In addition, there was no difference in the findings among NOACs. Elsevier 2017-04 2016-08-12 /pmc/articles/PMC5388056/ /pubmed/28416977 http://dx.doi.org/10.1016/j.joa.2016.07.011 Text en © 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Nagao, Tomoyuki Hunakubo, Hiroshi Suzuki, Mayu Kataoka, Takashi Okumura, Satoshi Shinoda, Norihiro Harada, Ken Kato, Bunichi Kato, Masataka Marui, Nobuyuki Sakai, Shinichi Amano, Tetsuya Murohara, Toyoaki Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants |
title | Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants |
title_full | Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants |
title_fullStr | Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants |
title_full_unstemmed | Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants |
title_short | Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants |
title_sort | trends in physiological coagulation factors in japanese patients receiving novel oral anticoagulants |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388056/ https://www.ncbi.nlm.nih.gov/pubmed/28416977 http://dx.doi.org/10.1016/j.joa.2016.07.011 |
work_keys_str_mv | AT nagaotomoyuki trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT hunakubohiroshi trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT suzukimayu trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT kataokatakashi trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT okumurasatoshi trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT shinodanorihiro trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT haradaken trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT katobunichi trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT katomasataka trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT maruinobuyuki trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT sakaishinichi trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT amanotetsuya trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants AT muroharatoyoaki trendsinphysiologicalcoagulationfactorsinjapanesepatientsreceivingnoveloralanticoagulants |